Immunoassay Research and Development Director

GREGORY W. SVANAS, Ph.D.

**** ******** **** 303-***-**** (cell)

Cincinnati, OH 45255 ********@*****.***

PH.D. PROTEIN BIOCHEMIST IMMUNOASSAY DIRECTOR with extensive experience in designing,

developing and commercializing immunoassays for a variety of analytes. Scientific management for successful

assay launch in lateral flow, microtiter, and latex agglutination formats. Identification of commercial antigen and

antibody sources, in addition to custom production of novel recombinant proteins and antibodies. Interdepartment

basic research to implement experimental assay platforms. Formulation optimization and manufacturing transfer,

including establishment of raw material specifications. production SOPs, and testing documents.

PROFESSIONAL EXPERIENCE

MERIDIAN BIOSCIENCE INC. – Cincinnati, OH 2010-2015

(Global medical diagnostics company with immunoassay and molecular products)

Scientist III

Led a group of 2-5 scientists investigating early research stage infectious disease assays

• Produced separate lateral flow immunoassays for Staphylococcus aureus and MRSA in blood cultures

with associated manufacturing documents

• Expressed and purified novel proteins used in production of monoclonal and polyclonal antibodies for

5 prototype assays simultaneously

WATERS CORPORATION – Arvada, CO 2008-2010

($1.9 billion international analytical instrument manufacturer)

Clinical Reagent Development Manager

Led a group of 3 to initiate a new business unit producing mass spectrometry calibrators for the hospital

laboratory

• Began implementation of a quality system to be consistent with cGMP regulations

• Installed LC/MS-MS system to establish quantitative testosterone assay protocols

CORGENIX MEDICAL CORPORATION – Broomfield, CO 2006-2008

(Global medical diagnostics company focused on autoimmune and cardiac biomarkers)

Project Director

Led a group of 2-4 scientists investigating novel biomarkers

• Completed assay validations for successful submission of serum IgG anti-AtherOx test to assess cardiac

risk

• Established prototype lateral flow immunoassay manufacturing system now being used for point-of-care

diagnosis of Ebola and Lassa viruses in Africa

BIOSTAR INC. Louisville, CO 1997-2006

($50 million infectious disease diagnostic company now owned by Alere, Inc.)

Associate Director

Led groups of 2-6 developing immunoassays for infectious diseases

• Developed urine concentration device for use with urine samples in sexually disease testing

• Developed new immunoassay protein target for Neisseria gonorrheae, resulting in first commercial rapid

test in male urine

• Developed sensitive Shiga toxin test to eliminate preliminary overnight culture

• Developed prototype rapid atypical pneumonia tests detecting Chlamydia pneumoniae and Mycoplasma

pneumonia

• Evaluated prototype immunoassay platform for walk-away testing of swab samples

• Coordinated clinical trials for the chlamydia, gonorrhea, and Shiga toxin tests

DDX, INC. – Denver, CO 1996-1997

G REGORY SVANAS PAGE 2-303-***-**** ********@*****.***

(Early stage research company developing new immunoassay platform, now owned by Accelerate Diagnostics)

Director of Assay Development

Led group of 8 scientists in developing immunoassays for food-borne disease and biodefense

• Began development of an immunoassay reader based on laser ellipsometry

• Sourced antibodies from commercial and private sources

SPECTRAL DIAGNOSTICS INC – Toronto, ON Canada 1993-1996

(Early stage diagnostics company developing point of care heart attack immunochromatography tests)

Director of Operations

Coordinated activities of manufacturing and quality departs of a 50-person company

• Supervised production of recombinant proteins for evaluation as human heart attack biomarkers

• Managed production of anti-troponin monoclonal antibodies still in use by diagnostic companies

• Liaison with outside company manufacturing the immunochromatography strips

WAMPOLE LABORATORIES – Cranbury, NJ 1992-1993

(Midsize diagnostic company focused on infectious diseases, now owned by Alere, Inc.)

Scientist

Led a group of 6 scientists developing latex agglutination serology assays for rubella

BAYER DIAGNOSTICS – Elkhart, IN 1987-1992

(Large international corporation focusing on immunoassay and urinary biomarkers now owned by Siemens

Healthcare)

Research Scientist

Led a group of 3 scientists developing immunoassays and urine test dip strips

• Initiated development of immunochromatography format

• Developed reagents for a vertical flow assay for Chlamydia trachomatis

• Evaluated new formulations of the urine glucose pad to reduce interference by ascorbic acid

EDUCATION

Post-doctoral Research on Liver Regeneration, University of Pittsburgh School of Medicine, Pittsburgh, PA

Ph.D. Biochemistry, Purdue University, West Lafayette, IN

BA Biology/Chemistry, Austin College, Sherman, TX

PROFESSIONAL ASSOCIATION MEMBERSHIPS

American Society for Microbiology

PEER-REVIEWED PUBLICATIONS

Teel LD, Daly JA, Jerris RC, Maul D, Svanas G, O'Brien AD, Park CH. “Rapid detection of Shiga toxin-

producing Escherichia coli by Optical Immunoassay.” J Clin Microbiol. 2007 Aug 45:3377-3380

Greco TP, Conti-Kelly AM, Matsuura E, Greco, Jr. T, Dier KJ, Svanas G, Doyle R, Lopez L. “Antiphospholipid

Antibodies in Patients with Coronary Artery Disease.” Ann NY Acad Sci 2007 Jun; 1108:466-74.

Penttila K, Penttila I, Bonnell R, Kerth P, Koukkunen H, Rantanen T, Svanas G. “Comparison of the troponin T and

troponin I ELISA tests, as measured by microplate immunoassay techniques, in diagnosing acute myocardial

infarction.” Eur J Clin Chem Clin Biochem. 1997 Oct; 35(10): 767-74.

Svanas GW, Eagon PK, Elm M, Makowka L, Podesta L, Chapchap P, Kahn D, Starzl TE, Van Thiel DH. “Effect of

antiandrogen flutamide on measures of hepatic regeneration in rats.” Dig Dis Sci. 1989 Dec; 34(12): 1916-23.

G REGORY SVANAS PAGE 3-303-***-**** ********@*****.***

Adler M, Gavaler JS, Duquesnoy R, Fung JJ, Svanas G, Starzl TE, van Thiel DH. “Relationship between the diagnosis,

preoperative evaluation, and prognosis after orthotopic liver transplantation.” Ann Surg. 1988 Aug; 208(2): 196-202.

Kahn D, Svanas GW, Eagon PK, Makowka L, Podesta L, Chapchap P, Starzl TE, Van Thiel DH. “Effect of an

antiandrogenic H2 receptor antagonist on hepatic regeneration in rats.” J Lab Clin Med. 1988 Aug; 112(2): 232-9.

Kahn D, Svanas GW, Eagon PK, Elm M, Porter LE, Makowka L, Podesta L, Chapchap P, Starzl TE, Van Thiel DH.

“Liver regeneration in rats treated with the antiandrogen flutamide.” J Invest Surg. 1988; 1(2): 133-8.

Adler M, Gavaler JS, Duquesnoy R, Fung J, Svanas G, Starzl TE, Van Thiel DH. “[Prognosis of hepatic transplantation

as a function of biological, immunological and functional preoperative findings]”

Acta Gastroenterol Belg. 1987 May-Jun; 50(3): 365-8. French.

Kam I, Lynch S, Svanas G, Todo S, Polimeno L, Francavilla A, Penkrot RJ, Takaya S, Ericzon BG, Starzl TE, et al.

“Evidence that host size determines liver size: studies in dogs receiving orthotopic liver transplants.”

Hepatology 1987 Mar-Apr; 7(2): 362-6.

Makowka L, Svanas G, Esquivel C, Venkataramanan R, Todo S, Iwatsuki S, Van Thiel D, Starzl TE. “Effect of

Cyclosporin on Hepatic Regeneration.” Surg Forum 1986; 37:352-354.

Svanas GW, Weiner H. “Enzymatic requirement for cyanamide inactivation of rat liver aldehyde dehydrogenase.”

Biochem Pharmacol. 1985 Apr 15; 34(8): 1197-204.

Svanas GW, Weiner H. “Use of cyanamide to determine localization of acetaldehyde metabolism in rat liver.”

Alcohol. 1985 Jan-Feb; 2(1): 111-5.

Svanas GW, Weiner H. “Aldehyde dehydrogenase activity as the rate-limiting factor for acetaldehyde metabolism in

rat liver.” Arch Biochem Biophys. 1985 Jan; 236(1): 36-46.

Svanas GW, Weiner H. “Identification of aldehyde dehydrogenase resistant to cyanamide and disulfiram inhibition.”

Alcohol 1984 Jul-Aug; 1(4): 347-9.

Svanas GW, Weiner H. “Rapid purification of dehydrogenases by affinity chromatography with ternary complexes.”

Anal Biochem. 1982 Aug; 124(2): 314-9.

Contact this candidate